Meet Longeveron Inc. (NASDAQ: $LGVN) In This Interview With CEO, Wa'el Hashad

Benzinga
Benzinga
  • 10 months ago
Longeveron is a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. Their lead investigational product is Lomecel-B™, which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors.

Recommended

8:01
I
Up next
Les tendances des "Biotech": Le Nasdaq Biotech a perdu 40% entre juillet 2015 et juin 2016, soit la plus forte correction depuis 10 ans - 19/20
BFM Business
2:28
There's shortage of black bone-marrow donors
South African Breaking News
5:19
Are You a Match? Here's Why We Need More Life-Saving Bone Marrow Donors
NBC Palm Springs
11:56
What's Up New York: Biotech, première IPO de l'année au Nasdaq - 26/01
BFM Business
6:56
Laurent Levy (Nanobiotix) : La Biotech française Nanobiotix s'introduit au Nasdaq - 17/12
BFM Business
10:08
Does Bone Marrow Contain The Keys To Curing Alzheimer's? BioTech Announces Promising Results From Clinical Trial
Benzinga
0:42
Trump Media Warns Nasdaq CEO of Potential Market Manipulation of DJT Stock, Raising Concerns of Naked Short Selling
Benzinga
11:25
How Amesite (NASDAQ: $AMST) Is Revolutionizing Learning With Artificial Intelligence
Benzinga
1:55
How Iteris' (NASDAQ: ITI) ClearGuide Analytics Are Revolutionizing Roadway Operations & Saving Lives
Benzinga
8:32
Candel Therapeutics (NASDAQ: $CADL): Revolutionizing Glioma Treatment and Redefining Hope
Benzinga
1:12
CAC 40, Nasdaq… La Bourse risque un krach éclair, JPMorgan tire la sonnette d’alarme
Capital
11:17
Unlocking the Power of 3D: Super League NASDAQ: $SLE Guides Brands Into The 3D World
Benzinga

Benzinga

0:54
Mike Tyson Returns to the Ring in Epic Showdown Against Jake Paul. VIP Package Offers $2 Million Ringside Seats for Historic Boxing Match
Benzinga
0:41
OpenAI to Launch AI-Powered Search Product, Aiming to Rival Google Search
Benzinga
0:46
Tesla Faces NLRB Complaint for Allegedly Hindering Unionization Efforts in Buffalo Plant
Benzinga
0:45
Sinclair Explores Sale of Over 30% of Broadcast Stations, Amid Tensions and Financial Losses
Benzinga
0:36
Apple iPad Pro Ad Sparks Outrage for Destruction of Creative Tools
Benzinga
0:39
Moderna's RSV Vaccine Approval Faces Setback as FDA Delays Decision
Benzinga

Featured channels

More from
TMZ
More from
Vogue
More from
The Hollywood Reporter
More from
Life Stories By Goalcast
More from
Veuer
More from
SportsGrid